Document:

Exhibit 10.3

 

FIRST AMENDMENT TO AMENDED 

AND RESTATED EMPLOYMENT AGREEMENT

 

This First Amendment to Amended and Restated Employment
Agreement (the “First Amendment”) is dated as of September 23, 2022 (the “First Amendment Effective Date”), between
Blueprint Medicines Corporation, a Delaware corporation (the “Company”), and Christina Rossi (the “Executive”).
Capitalized terms used and not defined herein shall have the meanings ascribed to such terms in the Employment Agreement (as defined below).

 

WHEREAS, the Company and the Executive are parties
to the Amended and Restated Employment Agreement dated January 4, 2022 and effective as of April 4, 2022 (the “Employment Agreement”);
and

 

WHEREAS, the Company and the Executive desire to
amend the Employment Agreement as set forth below;

 

NOW, THEREFORE, for good and valuable consideration,
the receipt of which is hereby confirmed, the Company and the Executive agree that the Employment Agreement is amended as follows:

 

1.            
Section 2 of the Employment Agreement shall be amended and restated as follows:

	 

 

“2.           Compensation and Related Matters.

 

(a)          
Base Salary. Effective as of the Effective Date, the Executive’s annual base salary shall be $581,510.00. The Executive’s
base salary shall be re-determined annually by the Board or the Compensation Committee of the Board (the “Compensation Committee”)
and shall be subject to increase but not decrease while Executive is serving in the Chief Operating Officer role. The annual base salary
in effect at any given time is referred to herein as “Base Salary.” The Base Salary shall be payable in a manner that is consistent
with the Company’s usual payroll practices for senior executives.

 

(b)         
 Equity. The Executive may be eligible to receive future equity awards under the Company’s 2015 Stock Option
and Incentive Plan (as amended and/or restated from time to time) or such other equity plan as then in effect, in the sole discretion
of the Board or the Compensation Committee.

 

(c)           
Incentive Compensation. During the Term, the Executive shall be eligible to earn cash incentive compensation as determined
by the Board or the Compensation Committee from time to time. More specifically:

 

(i)                 Effective
as of April 4, 2022, Executive’s target annual incentive compensation shall be 60% of the Base Salary, subject to upward but
not downward adjustment (except in connection with a proportional reduction in compensation to all or substantially all of the
Company’s employees). The Board or Compensation Committee shall weigh its bonus determination as follows: 75% on Company
performance and 25% on Executive’s individual performance, subject to adjustment as determined by the Board or the
Compensation Committee from time to time.

 

    - 1 -

     

    

 

(ii)               
For the period of January 1, 2022 through April 3, 2022, the Executive is eligible to earn prorated incentive compensation
under the Original Employment Agreement in connection with her services as Chief Commercial Officer of the Company during such period,
as determined by the Board or the Compensation Committee based on the Executive’s target annual incentive compensation equal to
50% of her annual base salary as in effect during such period (and the Board or the Compensation Committee shall weigh its bonus determination 75%
on Company performance and 25% on the Executive’s individual performance), provided the Executive remains employed by the Company
on the day such incentive compensation is paid.

 

(iii)             
The Executive’s target annual incentive compensation in effect at any given time is referred to herein as “Target
Incentive Compensation”; provided, that, for purposes of Section 5 hereof “Target Incentive Compensation” shall mean
the Executive’s target annual incentive compensation then in effect or, if higher, in effect immediately prior to the Sale Event,
and shall be applied to the Base Salary described in such section. To earn incentive compensation, the Executive must remain employed
by the Company in good standing through the date such incentive compensation is paid.

 

(d)           Expenses.
The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive during the Term
in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its
senior executive officers.

 

(e)           Other Benefits. During
the Term, the Executive shall be eligible to participate in or receive benefits under the Company’s employee benefit plans in effect
from time to time, subject to the terms of such plans.

 

(f)            Vacations. During the Term,
the Executive shall be entitled to paid vacation in accordance with the Company’s applicable policy.”

 

2.             The
Executive hereby gives express written consent in this First Amendment for the changes described herein. Accordingly, the Executive acknowledges
and agrees that the changes described herein shall not be the basis of a “Good Reason” trigger as defined in the Employment
Agreement, and therefore the Executive shall not be eligible to resign for Good Reason as a result of any such changes or in connection
with this First Amendment.

 

3.             To
the extent that there is any inconsistency between the terms and conditions of this First Amendment and the terms and conditions of the
Employment Agreement, the terms and conditions of this First Amendment shall prevail.

 

4.             This
First Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an
original, but such counterparts shall together constitute one and the same document. Counterparts may be delivered via facsimile,
electronic mail (including pdf or any electronic signature complying with the U.S. Federal ESIGN Act of 2000) or other transmission
method, and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all
purposes.

 

    - 2 -

     

    

 

5.             Except
as amended hereby, the Employment Agreement remains in full force and effect and, as amended hereby, the Employment Agreement represents
the entire agreement between the Executive and the Company, and there are no other agreements, written or oral, relating to the subject
matter hereof. On and after the First Amendment Effective Date, all references in the Employment Agreement to “this Agreement”
(including “hereof,” “herein” and similar words or phrases) shall mean the Employment Agreement, as amended by
this First Amendment.

 

IN WITNESS WHEREOF, the undersigned have executed
this First Amendment as of the date first written above. 

 

	 	BLUEPRINT MEDICINES CORPORATION
	 	 	 
	 	By:	/s/ Kathryn Haviland 
	 	Name:	Kathryn Haviland
	 	Title:	President and Chief Executive Officer
	 	 
	 	EXECUTIVE
	 	 
	 	/s/ Christina Rossi
	 	Christina Rossi

 

    - 3 -Exhibit 10.4

 

SECOND AMENDMENT TO EMPLOYMENT AGREEMENT

 

This Second Amendment to Employment Agreement (this
 “Second Amendment”) is dated as of September 23, 2022 (the “Second Amendment Effective Date”), between Blueprint
Medicines Corporation, a Delaware corporation (the “Company”), and Fouad Namouni, M.D. (the “Executive”). Capitalized
terms used and not defined herein shall have the meanings ascribed to such terms in the Employment Agreement (as defined below).

 

WHEREAS, the Company and the Executive are parties
to the Employment Agreement effective as of September 1, 2020, as amended by the First Amendment to Employment Agreement dated as of December
22, 2021 (collectively, the “Employment Agreement”); and

 

WHEREAS, the Company and the Executive desire to
amend the Employment Agreement as set forth below;

 

NOW, THEREFORE, for good and valuable consideration,
the receipt of which is hereby confirmed, the Company and the Executive agree that the Employment Agreement is amended as follows:

 

1.                 
Section 2(c) of the Employment Agreement shall be amended and restated as follows:

 

“Incentive Compensation. During the
Term, the Executive shall be eligible to earn cash incentive compensation as determined by the Board or the Compensation Committee from
time to time. Effective as of January 1, 2022, Executive’s target annual incentive compensation shall be 60% of the Base Salary,
subject to upward but not downward adjustment (except in connection with a proportional reduction in compensation to all or substantially
all of the Company’s employees). The Board or Compensation Committee shall weigh its bonus determination as follows: 75% on Company
performance and 25% on Executive’s individual performance, subject to adjustment as determined by the Board or the Compensation
Committee from time to time. The Executive’s target annual incentive compensation in effect at any given time is referred to herein
as “Target Incentive Compensation”; provided, that, for purposes of Section 5 hereof “Target Incentive Compensation”
shall mean the Executive’s target annual incentive compensation then in effect or, if higher, in effect immediately prior to the
Sale Event, and shall be applied to the Base Salary described in such section. To earn incentive compensation, the Executive must remain
employed by the Company in good standing through the date such incentive compensation is paid.”

 

2.                 
The Executive hereby gives express written consent in this Second Amendment for the changes described herein. Accordingly, the
Executive acknowledges and agrees that the changes described herein shall not be the basis of a “Good Reason” trigger as defined
in the Employment Agreement, and therefore the Executive shall not be eligible to resign for Good Reason as a result of any such changes
or in connection with this Second Amendment.

 

3.                 
To the extent that there is any inconsistency between the terms and conditions of this Second Amendment and the terms and conditions
of the Employment Agreement, the terms and conditions of this Second Amendment shall prevail.

 

    - 1 -

     

    

 

4.                 
This Second Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be taken
to be an original, but such counterparts shall together constitute one and the same document. Counterparts may be delivered via facsimile,
electronic mail (including pdf or any electronic signature complying with the U.S. Federal ESIGN Act of 2000) or other transmission method,
and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

5.                 
Except as amended hereby, the Employment Agreement remains in full force and effect and, as amended hereby, the Employment Agreement
represents the entire agreement between the Executive and the Company, and there are no other agreements, written or oral, relating to
the subject matter hereof. On and after the Second Amendment Effective Date, all references in the Employment Agreement to “this
Agreement” (including “hereof,” “herein” and similar words or phrases) shall mean the Employment Agreement,
as amended by this Second Amendment.

 

IN WITNESS WHEREOF, the undersigned have executed
this Second Amendment as of the date first written above.

 

	 	BLUEPRINT MEDICINES CORPORATION
	 	 	 
	 	By:	/s/ Kathryn Haviland
	 	Name:	Kathryn Haviland
	 	Title:	President and Chief Executive Officer
	 	 
	 	EXECUTIVE
	 	 
	 	/s/ Fouad Namouni 
	 	Fouad Namouni, M.D.

 

    - 2 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]